Vitamin K Antagonist (Phenprocoumon) and Subarachnoid Hemorrhage: A Single-Center, Matched-Pair Analysis.
Adult
Aged
Aneurysm, Ruptured
/ complications
Angiography, Digital Subtraction
Anticoagulants
/ therapeutic use
Cerebral Angiography
Female
Functional Status
Humans
Intracranial Aneurysm
/ complications
Male
Matched-Pair Analysis
Middle Aged
Mortality
Phenprocoumon
/ therapeutic use
Prognosis
Risk Factors
Rupture, Spontaneous
Severity of Illness Index
Subarachnoid Hemorrhage
/ etiology
Vasospasm, Intracranial
/ epidemiology
Cerebral vasospasm
Intracranial aneurysm
Phenprocoumon
Subarachnoid hemorrhage
Vitamin K antagonist
Warfarin
Journal
Neurocritical care
ISSN: 1556-0961
Titre abrégé: Neurocrit Care
Pays: United States
ID NLM: 101156086
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
30
10
2019
medline:
17
8
2021
entrez:
30
10
2019
Statut:
ppublish
Résumé
Demographic changes are leading to an aging society with a growing number of patients relying on anticoagulation, and vitamin K antagonists (VKA) are still widely used. As mortality and functional outcomes are worse in case of VKA-associated hemorrhagic stroke, phenprocoumon treatment seems to be a negative prognostic factor in case of subarachnoid hemorrhage (SAH). The purpose of this study was to analyze whether phenprocoumon treatment does worsen the outcome after non-traumatic SAH. All patients treated for non-traumatic SAH between January 2007 and December 2016 in our institution were retrospectively analyzed. After exclusion of patients with anticoagulant or antiplatelet treatment other than phenprocoumon, we analyzed 1040 patients. Thirty-three patients (3%) of those were treated with continuous phenprocoumon. In total, 132 out of all 1007 patients without anticoagulant treatment of the remaining patients were matched as control group (ratio = 1:4). Patients with phenprocoumon treatment were significantly older (66.5 years vs. 53.9 years; p < .0001), and admission status was significantly more often poor (66.7% vs. 41.8%, p = .007) compared to all patients without anticoagulant treatment. Further, bleeding pattern and rates of early hydrocephalus did not differ. Matched-pair analysis revealed a significant higher rate of angio-negative SAH in the study group (p = .001). Overall rates of hemorrhagic or thromboembolic complications did not differ (21.4% vs. 18.8%; NS) but were more often fatal, and 30-day mortality rate was significantly higher in the phenprocoumon group than in patients of the matched-pair control group (33% vs. 24%; p < .001). 30% of the phenprocoumon group and 37% of the matched-pair control group reached favorable outcome. However, poor outcome was strong associated with the reason for phenprocoumon treatment. Patients with phenprocoumon treatment at the time of SAH are significantly older, admission status is worse, and 30-day mortality rates are significantly higher compared to patients without anticoagulant treatment. However, outcome at 6 months did not differ to the matched-pair control group but seems to be strongly associated with the underlying cardiovascular disease. Treatment of these patients is challenging and should be performed on an interdisciplinary base in each individual case. Careful decision-making regarding discontinuation and bridging of anticoagulation and close observation is mandatory.
Sections du résumé
BACKGROUND
Demographic changes are leading to an aging society with a growing number of patients relying on anticoagulation, and vitamin K antagonists (VKA) are still widely used. As mortality and functional outcomes are worse in case of VKA-associated hemorrhagic stroke, phenprocoumon treatment seems to be a negative prognostic factor in case of subarachnoid hemorrhage (SAH). The purpose of this study was to analyze whether phenprocoumon treatment does worsen the outcome after non-traumatic SAH.
METHODS
All patients treated for non-traumatic SAH between January 2007 and December 2016 in our institution were retrospectively analyzed. After exclusion of patients with anticoagulant or antiplatelet treatment other than phenprocoumon, we analyzed 1040 patients. Thirty-three patients (3%) of those were treated with continuous phenprocoumon. In total, 132 out of all 1007 patients without anticoagulant treatment of the remaining patients were matched as control group (ratio = 1:4).
RESULTS
Patients with phenprocoumon treatment were significantly older (66.5 years vs. 53.9 years; p < .0001), and admission status was significantly more often poor (66.7% vs. 41.8%, p = .007) compared to all patients without anticoagulant treatment. Further, bleeding pattern and rates of early hydrocephalus did not differ. Matched-pair analysis revealed a significant higher rate of angio-negative SAH in the study group (p = .001). Overall rates of hemorrhagic or thromboembolic complications did not differ (21.4% vs. 18.8%; NS) but were more often fatal, and 30-day mortality rate was significantly higher in the phenprocoumon group than in patients of the matched-pair control group (33% vs. 24%; p < .001). 30% of the phenprocoumon group and 37% of the matched-pair control group reached favorable outcome. However, poor outcome was strong associated with the reason for phenprocoumon treatment.
CONCLUSION
Patients with phenprocoumon treatment at the time of SAH are significantly older, admission status is worse, and 30-day mortality rates are significantly higher compared to patients without anticoagulant treatment. However, outcome at 6 months did not differ to the matched-pair control group but seems to be strongly associated with the underlying cardiovascular disease. Treatment of these patients is challenging and should be performed on an interdisciplinary base in each individual case. Careful decision-making regarding discontinuation and bridging of anticoagulation and close observation is mandatory.
Identifiants
pubmed: 31659679
doi: 10.1007/s12028-019-00868-4
pii: 10.1007/s12028-019-00868-4
doi:
Substances chimiques
Anticoagulants
0
Phenprocoumon
Q08SIO485D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105-114Références
Saliba W. Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation. Am J Cardiovasc Drugs. 2015;15:323–35.
doi: 10.1007/s40256-015-0124-5
Frontera JA, Lewin JJ III, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage. Neurocrit Care. 2016;24:6–46.
doi: 10.1007/s12028-015-0222-x
Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007;120:700–5.
doi: 10.1016/j.amjmed.2006.07.034
Wilke A, Wende CM, Horst M, Steverding D. Thrombosis of a prosthetic mitral valve after withdrawal of phenprocoumon therapy. Cardiol Res. 2011;2:298–300.
pubmed: 28352399
pmcid: 5358259
Bruder M, Schuss P, Konczalla J, El-Fiki A, Lescher S, Vatter H, et al. Ventriculostomy-related hemorrhage after treatment of acutely ruptured aneurysms: the influence of anticoagulation and antiplatelet treatment. World Neurosurg. 2015;84:1653–9.
doi: 10.1016/j.wneu.2015.07.003
Bruder M, Schuss P, Berkefeld J, Wagner M, Vatter H, Seifert V, et al. Subarachnoid hemorrhage and intracerebral hematoma caused by aneurysms of the anterior circulation: Influence of hematoma localization on outcome. Neurosurg Rev. 2014;37:653–9.
doi: 10.1007/s10143-014-0560-8
Konczalla J, Platz J, Brawanski N, Güresir E, Lescher S, Senft C, et al. Endovascular and surgical treatment of internal carotid bifurcation aneurysms. Neurosurgery. 2015;76:540–51.
doi: 10.1227/NEU.0000000000000672
Konczalla J, Kashefiolasl S, Brawanski N, Senft C, Seifert V, Platz J. Increasing numbers of nonaneurysmal subarachnoid hemorrhage in the last 15 years: antithrombotic medication as reason and prognostic factor? J Neurosurg. 2016;124:1731–7.
doi: 10.3171/2015.5.JNS15161
Konczalla J, Brawanski N, Bruder M, Senft C, Platz J, Seifert V. Outcome of patients with long-lasting cerebral vasospasm after subarachnoid hemorrhage: is prolonged treatment for cerebral vasospasm worthwhile? A matched-pair analysis. World Neurosurg. 2016;88:488–96.
doi: 10.1016/j.wneu.2015.10.033
Platz J, Güresir E, Schuss P, Konczalla J, Seifert V, Vatter H. The impact of the body mass index on outcome after subarachnoid hemorrhage. Neurosurgery. 2013;73:201–8.
doi: 10.1227/01.neu.0000430322.17000.82
Raabe A, Beck J, Keller M, Vatter H, Zimmermann M, Seifert V. Relative importance of hypertension compared with hypervolemia for increasing cerebral oxygenation in patients with cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg. 2005;103:974–81.
doi: 10.3171/jns.2005.103.6.0974
Nieuwkamp DJ, Rinkel GJE, Silva R, Greebe P, Schokking DA, Ferro JM. Subarachnoid haemorrhage in patients >=75 years: clinical course, treatment and outcome. J Neurol Neurosurg Psychiatry. 2006;77:933–7.
doi: 10.1136/jnnp.2005.084350
Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980;6:1–9.
doi: 10.1227/00006123-198001000-00001
Rosen DS, Macdonald RL, Huo D, Goldenberg FD, Novakovic RL, Frank JI, et al. Intraventricular hemorrhage from ruptured aneurysm: clinical characteristics, complications, and outcomes in a large, prospective, multicenter study population. J Neurosurg. 2007;107:261–5.
doi: 10.3171/JNS-07/08/0261
Platz J, Güresir E, Wagner M, Seifert V, Konczalla J. Increased risk of delayed cerebral ischemia in subarachnoid hemorrhage patients with additional intracerebral hematoma. J Neurosurg. 2017;126:504–10.
doi: 10.3171/2015.12.JNS151563
Konczalla J, Seifert V, Beck J, Güresir E, Vatter H, Raabe A, et al. Outcome after Hunt and Hess Grade V subarachnoid hemorrhage: a comparison of pre-coiling era (1980–1995) versus post-ISAT era (2005–2014). J Neurosurg. 2018;128:100–10.
doi: 10.3171/2016.8.JNS161075
Sekhon JS. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. JSS J Stat Softw. 2011;42:1–52. https://doi.org/10.18637/jss.v042.i07
doi: 10.18637/jss.v042.i07
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322.
pubmed: 25520374
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:141.
doi: 10.1136/bmj.324.7330.141
Beynon C, Nofal M, Rizos T, Laible M, Potzy A, Unterberg AW, et al. Anticoagulation reversal with prothrombin complex concentrate in aneurysmal subarachnoid hemorrhage. J Emerg Med. 2015;49:778–84.
doi: 10.1016/j.jemermed.2015.05.032
Olsen M, Johansen MB, Christensen S, Sørensen HT. Use of vitamin K antagonists and risk of subarachnoid haemorrhage: a population-based case-control study. Eur J Intern Med. 2010;21:297–300.
doi: 10.1016/j.ejim.2010.04.009
Risselada R, Straatman H, van Kooten F, Dippel DWJ, van der Lugt A, Niessen WJ, et al. Platelet aggregation inhibitors, vitamin K antagonists and risk of subarachnoid hemorrhage. J Thromb Haemost. 2011;9:517–23.
doi: 10.1111/j.1538-7836.2010.04170.x
Tarlov N, Norbash AM, Nguyen TN. The safety of anticoagulation in patients with intracranial aneurysms. J Neurointerv Surg. 2013;5:405–9.
doi: 10.1136/neurintsurg-2012-010359
Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy. Stroke. 2005;36:1588–93.
doi: 10.1161/01.STR.0000170642.39876.f2
Ellis JA, McDowell MM, Mayer SA, Lavine SD, Meyers PM, Connolly ES. The role of antiplatelet medications in angiogram-negative subarachnoid hemorrhage. Neurosurgery. 2014;75:530–5 (discussion 534-5).
doi: 10.1227/NEU.0000000000000490
Frontera JA, Gordon E, Zach V, Jovine M, Uchino K, Hussain MS, et al. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. Neurocrit Care. 2014;21:397–406.
doi: 10.1007/s12028-014-9972-0
Woo CH, Patel N, Conell C, Rao VA, Faigeles BS, Patel MC, et al. Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. World Neurosurg. 2014;81:110–5.
doi: 10.1016/j.wneu.2012.12.002
Tazarourte K, Riou B, Tremey B, Samama C-M, Vicaut É, Vigué B, et al. Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study). Crit Care. 2014;18:R81.
doi: 10.1186/cc13843
Konczalla J, Schmitz J, Kashefiolasl S, Senft C, Seifert V, Platz J. Non-aneurysmal subarachnoid hemorrhage in 173 patients: a prospective study of long-term outcome. Eur J Neurol. 2015;22:1329–36.
doi: 10.1111/ene.12762
Cánovas D, Gil A, Jato M, de Miquel M, Rubio F. Clinical outcome of spontaneous non-aneurysmal subarachnoid hemorrhage in 108 patients. Eur J Neurol. 2012;19:457–61.
doi: 10.1111/j.1468-1331.2011.03542.x
Beseoglu K, Pannes S, Steiger HJ, Hänggi D. Long-term outcome and quality of life after nonaneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien). 2010;152:409–16.
doi: 10.1007/s00701-009-0518-8